Latest Leverage News

Element 25 Limited reports a transformative quarter with a 142% resource increase at Butcherbird, a compelling $561 million NPV feasibility study, and a $268 million US Department of Energy grant to advance its Louisiana battery-grade manganese refinery.

Farm Pride Foods has successfully recovered from Avian Influenza setbacks, improving cash flows and repaying significant debt while investing in biosecurity and production upgrades.

Suvo Strategic Minerals delivered a robust December quarter with soaring profits and an extended supply deal, while advancing innovative low carbon cement projects in Australia and Indonesia.

AML3D Limited has reported a strong December quarter marked by significant defense contract completions, a $30 million capital raise, and strategic expansion into the US and European markets. The company is poised for accelerated growth, underpinned by a major US Navy funding boost and new sector entries.

Latrobe Magnesium marks a year without lost time injuries and completes key construction phases, while navigating legal disputes and operational cost pressures.

88 Energy Limited announces a maiden internal Prospective Resource estimate of 283 million barrels of oil for its Canning Prospect at Project Leonis, Alaska, with plans to drill the Tiri-1 exploration well targeting multiple reservoirs in 2026.

Saturn Metals has engaged global heap leach engineering leader Kappes Cassiday & Associates to complete the Pre-Feasibility Study for its Apollo Hill Gold Project, marking a pivotal step in advancing the project’s development.

Kingsrose Mining, in alliance with BHP, reports promising high-grade copper and polymetallic discoveries in Norway and Finland, advancing one of Europe’s largest exploration programs.

Tryptamine Therapeutics has reported successful Phase 1b results for its IV-infused psilocin candidate TRP-8803 and promising interim data for oral psilocybin TRP-8802 in IBS treatment, while securing $6 million in new funding to accelerate clinical development.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

OpenLearning Limited reported a 23% year-on-year increase in SaaS annual recurring revenue to $2.335 million in Q4 FY24, driven by strong growth in AI-powered products and strategic partnerships. The company also cut net operating cash outflows by over half, signaling improved operational efficiency.

Atomo Diagnostics reports a robust Q2 FY25 with $1.2 million revenue driven by HIV self-test sales and a significant $2.44 million government grant for syphilis test development. The company advances its market footprint in Australia and New Zealand while maintaining a strong cash position.